Sugi Predict

Sugi Predict / Compounds / SCHEMBL2847723

SCHEMBL2847723

SCHEMBL2847723

c1nc(Oc2ccc3nc(NCC4CCCCC4)sc3c2)c2sccc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 9/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ KIT P10721 2/20 0.38
▸ PDGFRA P16234 2/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ PDGFRB P09619 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ PI4KA P42356 3/20 0.37
▸ PIK3CG P48736 3/20 0.37
▸ PI4KB Q9UBF8 3/20 0.37
▸ PIK3CA P42336 2/20 0.37
▸ NR2C2 P49116 1/20 0.37
▸ TAB1 Q15750 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2848745 0.86 CSF1R (0.43) CSF1RNPC1MAPTRAB9APKM
SCHEMBL2842981 0.83 PDGFRA (0.58) KITPDGFRAPDGFRB
SCHEMBL2844397 0.78 CSF1R (0.49) CSF1RNPC1MAPTRAB9APKM
SCHEMBL2845197 0.78 NPC1 (0.43) CSF1RNPC1MAPTRAB9APKM
SCHEMBL2845044 0.78 KDR (0.46) CSF1RNPC1MAPTRAB9APKM
SCHEMBL2677488 0.77 CSF1R (0.55) CSF1RNPC1MAPTRAB9APKM
SCHEMBL2843153 0.77 MAPT (0.44) CSF1RNPC1MAPTRAB9APKM
SCHEMBL2677745 0.77 RAB9A (0.59) NPC1MAPTRAB9AITK
SCHEMBL2676754 0.76 CSF1R (0.48) CSF1RNPC1MAPTRAB9APKM
SCHEMBL2677134 0.76 CSF1R (0.48) CSF1RNPC1MAPTRAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 — — EP claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US claimed
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 — — EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885NPC1 2714/4885MAPT 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.